Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization

Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.

Subsidie
€ 2.226.280
2023

Projectdetails

Introduction

Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of triggering an efficient immune response against cancer.

Current Limitations

Currently, there is no standard method to identify antigens, and the few methods available have significant limitations by being quite long, complicated, and resource-demanding.

PeptiCHIP Introduction

In response to this clear technological and market gap, Valo Therapeutics (ValoTx, an immunotherapy development company) is introducing PeptiCHIP, i.e., an innovative microfluidic immunopurification device and a peptide prioritization algorithm to identify the most relevant (neo)antigens to stimulate the immune system and thus increase the chance of success of the immunotherapy.

Adaptability and Proof of Concept

PeptiCHIP can be adapted and used to identify antigens related to any disease. The Proof of Concept (PoC) was successfully demonstrated at the University of Helsinki. The IP was protected, and ValoTx has full rights to further develop, exploit, and commercialize PeptiCHIP.

Project Goals

This EIC Transition project will allow further technology development, testing, validating, and demonstrating it pre-clinically, generating evidence to convince investors and stakeholders, as well as to prepare an extensive and solid transition-to-market plan (T2MP).

Impact Areas

By being accurate, fast, low-cost, easy to use, and working with very small amounts of samples, PeptiCHIP will have a great impact in:

  1. Research: For discovery & new therapies development since identification of antigens allows the understanding of diseases & immune response mechanisms.
  2. Industry: For therapy development & translation into clinical use since the antigens identification & prioritization is a critical step to produce therapies tailored for each patient to ensure responsiveness.
  3. Clinic: For patient assessment & immunotherapy tailoring.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.226.280
Totale projectbegroting€ 2.226.280

Tijdlijn

Startdatum1-4-2023
Einddatum30-9-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • VALO THERAPEUTICS OYpenvoerder

Land(en)

Finland

Vergelijkbare projecten binnen EIC Transition

EIC Transition

Very High Energy Electrons Beam for Radiotherapy

eBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects.

€ 2.477.043
EIC Transition

High-throughput hyperspectral imaging across the VIS-SWIR spectrum in a single device

The HYPERIA project aims to develop a novel hyperspectral imaging camera using Fourier Transform interferometry for enhanced sensitivity and wavelength range, targeting applications in food safety and waste separation.

€ 1.500.000
EIC Transition

Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung Adenocarcinoma

This project aims to develop Antisense Oligonucleotides to correct pathological splicing of the NUMB gene in lung adenocarcinomas, improving treatment efficacy and paving the way for clinical trials.

€ 2.899.553
EIC Transition

Photonic chip based high-throughput, multi-modal and scalable optical nanoscopy platform

NanoVision aims to revolutionize optical nanoscopy with an affordable, compact, and high-throughput photonic-chip solution, enhancing accessibility and flexibility for research and clinical labs.

€ 2.489.571

Vergelijkbare projecten uit andere regelingen

ERC COG

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.

€ 1.993.875
ERC POC

Neoantigen Identification with Dendritic Cell Reprogramming

The NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies.

€ 150.000
ERC POC

Fast and simple biomarker detection by computational microscopy

We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.

€ 150.000
EIC Accelerator

IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.

The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.

€ 2.496.112